USFDAJul 29, 2026, 08:07 AM
Enlivex to Host Webinar on Private Placement & Allocetra RMAT Designation
AI Summary
Enlivex Ltd. announced that its management team will host a live webinar on Thursday, July 30, 2026, to provide investors with additional details. The webinar will cover the recently announced private placement, the status and strategy of its RAIN treasury, and recent clinical progress for Allocetra. Notably, Allocetra has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for the treatment of symptomatic knee osteoarthritis in patients aged 64 and older.
Key Highlights
- Enlivex management to host a live webinar on July 30, 2026, at 10:00 AM ET.
- Webinar will discuss the recently announced private placement and its rationale.
- Company will provide an update on its RAIN treasury status and strategy.
- Clinical progress for Allocetra will be reviewed, including the ongoing Phase 2b trial.
- Allocetra received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
- RMAT designation is for Allocetra in treating symptomatic knee osteoarthritis in patients aged 64 and older.
Price Impact
More from ENLV